Introduction
The paraneoplastic neurologic disorders are a varied group of cancer-related neurologic disorders that are known or suspected to be immune-mediated. The tumors most commonly associated with PND are those that express neuroendocrine proteins, such as small-cell lung cancer (SCLC), tumors that contain nervous tissue, such as teratomas, and tumors that affect organs with immunoregulatory functions, such as thymoma. Less common but often associated with highly typical neurologic syndromes are neoplasms of the ovary, breast, and germ-cell tumors of the testis. A variety of paraneoplastic neuropathies are found in association with leukemias, lymphoma, plasma cell dyscras i a s , a n d r e l a t e d d i s o r d e r s . T h e s e d i v e r s e neuropath ic syndromes will not be further discussed and are reviewed elsewhere [1•, 2•].
For a patient without a cancer diagnosis, the identification of PND is straightforward if they develop a neurologic syndrome typically associated with cancer (Table 1) . It is generally recommended that any patient who develops one of these "classic" PND syndromes undergo cancer screening initially focused on the most commonly associated cancers. The presence of a specific antineuronal ant i b o d y i n s e r u m o r C S F w i l l c o n f i r m a paraneoplastic etiology. If no cancer is found, a more extensive evaluation should be done as rare cancer-antibody associations do occur. In almost 90 % of patients with PNDs associated with solid tumors, the underlying cancer will be uncovered either at PND presentation or within the first year. Patients in whom PND is strongly suspected but no cancer is identified should undergo periodic cancer screening for at least 5 years.
In patients with a cancer diagnosis, the suspicion that new neurologic symptoms are paraneoplastic in origin is based on whether the neurologic syndrome is typically associated with the patients' cancer type or antineuronal antibody, if present, and the absence of other etiologies, including side effects of cancer treatment. Patients in cancer remission who develop typical PND syndromes should be examined for tumor recurrence. General guidelines for cancer screening in patients with PND have been proposed and can help direct the evaluation [3] .
The diagnosis of PND is more difficult in patients whose neurologic syndromes may be paraneoplastic but more commonly occur without a cancer association ( Table 2) . Some of these patients have antineuronal antibodies that associate with the neurologic syndrome but occur in patients both with and without cancer and thus are not specific for PND (Table 2) [4•]. The need for an oncologic evaluation is based on the syndrome, clinical suspicion for a cancer, and if present the antibody. For example most patients with myasthenia gravis have antiacetylcholine receptor antibodies but only 15 % of cases are paraneoplastic. However, due to the strong association with thymoma, it is recommended that all newly diagnosed patients undergo screening for this specific tumor. In contrast, Guillain-Barré syndrome may be a paraneoplastic manifestation of Hodgkins' lymphoma and less commonly a systemic cancer. The lack of specificity for any one cancer type and the relatively infrequent occurrence of Guillain-Barré as a PND argues against routine cancer screening unless there is clinical or laboratory evidence that suggests an underlying cancer [5] . In some cases the co-occurrence of a neurologic syndrome and cancer may simply be coincidental. A paraneoplastic relationship is suggested but not proven by evidence of nervous system inflammation, an atypical presentation or course of the neurologic disease, or response to immunotherapies.
For most PND, neuroimaging with magnetic resonance imaging (MRI) is more important to rule out other causes of neurologic dysfunction, such as compression by metastatic lesions, or to detect leptomeningeal metastases rather than to make the diagnosis of PND as in many PND neuroimaging will be normal. The main exception is in limbic encephalitis in which abnormalities may be demon- *In addition to treatment directed to the tumor; SCLC, small-cell lung cancer; CRMP, collapsin response-mediator protein; GAD, glutamic acid decarboxylase.
strated using T2 and fluid-attenuated inversion recovery (FLAIR) sequences that likely represent the ongoing inflammatory process in the nervous system [6, 7] . The radiologist should be made aware of the possible limbic encephalitis diagnosis so that special attention is given to these sequences. Brain [F18] fluorodeoxyglucose-positron emission tomography (FDG-PET) in the early stages of some PND o f t h e c e n t r a l n e r v o u s s y s t e m m a y s h o w hypermetabolism in some regions even when MRI *In addition to treatment directed to the tumor; SCLC, small-cell lung cancer; VGCC, voltage-gated calcium channel; AChR, acetylcholine receptor; Caspr2, contactin-associated protein 2; NMDAR, N-methyl D-aspartate receptor; AMPAR, α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor; LGI1, leucine-rich glioma inactivated 1; GABA(B), Gamma-amino-butyric acid type B; mGluR1, metabotropic glutamate receptor-5; mGluR5, metabotropic glutamate receptor-5.
is normal and is likely indicative of the early stages of the inflammatory process [8, 9, 10•] . Cerebellar atrophy may be seen at the end stages of cerebellar degeneration.
Antineuronal antibodies
The specificity of some antineuronal antibodies for certain PND or some types of cancer helps diagnose the PND and focus the oncologic evaluation (Table 1) . The presence of any of these antibodies (including anti-Hu, Yo, CV2/CRMP5, Ri, Ma2, Tr, and amphiphysin) is almost invariably associated with cancer and if a cancer is not discovered, the presence of an occult neoplasm must be assumed. However, all PND can occur in the absence of antibodies and antibodies are detectable at low titers in the serum of some patient with cancer without PND [11] . However, the finding of high titers of antibodies in serum or of any titer of antibodies in the CSF is strongly supportive of PND. For those PND that affect the central nervous system, antibody titers in CSF will be higher than in serum or the serum may be negative for antibodies, so it is recommended that CSF be studied in all suspected cases.
Treatment
For treatment purposes, the immune-mediated PND can be divided into those in which the antibodies are pathogenic and those in which cytotoxic T cells are the main effectors of the neurologic dysfunction. When antibodies are pathogenic the target antigens are mostly neuronal cell surface or synaptic proteins whose function is disrupted by the antibody [12] [13] [14] . In these disorders, antibody removal often results in neurologic improvement. However, antibody-depleting strategies are much more effective when the target antigens are in the periphery (e.g., myasthenia gravis or Lambert-Eaton myasthenic syndrome) as plasma exchange and intravenous immunoglobulins (IVIg) are not very effective at decreasing intrathecal antibody titers. For those antibody-mediated disorders of the central nervous system (e.g., anti-NMDA receptor encephalitis), additional immunotherapies often are required [15•] . For those PND that are likely T-cell mediated (e.g., anti-Hu associated encephalomyelitis), immunosuppression or immunomodulation is recommended, but responses are less likely as irreversible neuronal damage appears to occur rapidly and early [16] . For these PND, data demonstrate a better chance for improvement or stabilization of the PND if immunotherapies are started when the neurologic deficits are not fully established [17, 18] . Exceptions include limbic encephalitis in young men with testicular tumors and anti-Ma2 antibodies and stiff-person syndrome associated with anti-amphiphysin antibodies [19] .
Treatment of the tumor
For all PND, prompt identification and treatment of the tumor is important as this has been found in several series to be the main factor associated with stabilization or improvement of the PND [18, 20] . Patients should be approached and treated as those without PND. Although surgeons are reluctant to take critically ill patients for tumor resection, patients with PND should be quickly and aggressively treated. As an example, patients in intensive care units with anti-NMDA receptor encephalitis tolerate tumor resection and immunotherapies and data shows that these procedures shorten time to recovery and increase the likelihood of full recovery [15•] .
Treatment of the PND
Treatments directed at the PND are primarily immunosuppressive and immunomodulatory. Initial therapies often include corticosteroids, plasma exchange, IVIg, and/or rituximab. More aggressive second-line immunosuppression with cyclophosphamide, tacrolimus, or cyclosporine among others, may be used when there is no response to initial treatments and the patient is still losing neurological functions. There are few studies proving efficacy, although several retrospective and small prospective studies support benefit of immunosuppression for some patients and syndromes [15•, 18, 21, 22] . Concerns that the use of immunosuppression in cancer patients will favor tumor growth are not supported by available studies; however, the simultaneous use of some immunosuppressants and oncologic treatments may result in increased toxicity requiring coordination of care between subspecialities.
Pharmacological therapies
Few trials have examined optimal treatment strategies for PND. Most treatments are empirically based on data from other autoimmune diseases and reports from cases series and cohort studies. Thus there are no standard dosing regimens specific to PND.
Corticosteroids
Corticosteroids are commonly and empirically used in conjunction with other treatments such as IVIg or plasma exchange.
Dosing Methylprednisolone 1000 mg /day I.V. for 3 to 5 days is often used initially or in repeating monthly courses. Prednisone 1 mg/kg P.O. daily or 60-80 mg daily may be used as maintenance therapy followed by slow tapering.
Contraindications Patients with diabetes, underlying infections, hypertension or peptic ulcer disease need to be monitored closely.
Main drug interactions None.
Main side effects hyperglycemia, hypertension, leukocytosis, thrombocytosis, peptic ulceration, insomnia, osteoporosis.
Cost/cost effectiveness Relatively inexpensive.
Cyclophosphamide
Cyclophosphamide is a broad immunosuppressive agent that decreases both humoral and cellular immunity.
Dosing Varying dosing regimens have been reported in small series. These include 750 mg/m 2 (body surface area) infused over 1 hour once every 4 weeks; fixed dose of 500 mg per day for 2-4 days per month, or a fixed monthly dose of 1000 mg. All regimens were given I.V.
Contraindications Patients with diabetes, underlying infections, hypertension or peptic ulcer disease need to be monitored closely. Not to be used during pregnancy.
Main drug interactions Allopurinol.
Main side effects Nausea, vomiting, myelosuppression, headache, dizziness, hemorrhagic cystitis.
Special points Increased risk of myelo-or lymphoproliferative malignancies. The above noted doses do not require Mesna to prevent hemorrhagic cystitis.
Cost/cost-effectiveness Cyclophosphamide is relatively inexpensive however costs are increased due to the need for intravenous hydration and laboratory monitoring.
Intravenous Immunoglobulin
Despite use over many years, the mechanisms by which IVIg modulates immune function are not well understood, but it appears to decrease T-cell proliferation, suppress B-cell differentiation, and decrease levels of pro-inflammatory cytokines [23] . Thus, it has broad range of action and has been used in almost all PND.
Dosing There is no standard dose. Some patients have received 0.4 gm/kg per day for 3 to 5 consecutive days each month (total dose no more than 2 gm/kg) while others have used 2 gm/kg per month (divided into 2 consecutive daily doses of 1 gm/kg) for three months.
Contraindications IgA deficiency, previous hypersensitivity, hyperviscosity syndrome, vascular disease, renal insufficiency.
Main drug interactions None.
Main side effects Headache, nausea, fever, aseptic meningitis.
Special points The use of 60 mg I.V. methylprednisolone may decrease the severity of headache.
Cost/cost-effectiveness Very expensive.
Rituximab
Rituximab is mostly reserved for those disorders in which antibodies are pathogenic (e.g., anti-NMDA receptor encephalitis) as antibody depleting strategies, such as plasma exchange and IVIg, are far more effective in depleting peripheral but not central nervous system antibody titers [22] . Furthermore, the depletion of intrathecal B-cells produced by rituximab is durable and can last for 8 or more months [24, 25] .
Dosing Most practitioners use the same dosing as that in patients with lymphoma: 375 mg/m 2 every week for 4 weeks.
Contraindications Allergy to mouse proteins and patients with cardiac disease.
Main drug interactions Use of live virus vaccines.
Main side effects Hypersensitivity with first infusion including fever, chills, headache, and hypotension.
Special points Infusion reactions can be mitigated by pretreatment with intravenous corticosteroids, anti-histaminics and acetaminophen.
Cost/cost-effectiveness Expensive.
Mycophenolate Mofetil
Mycophenolate has been used for long-term immunosuppression and may be useful in disorders, such as anti-NMDA receptor encephalitis in which relapses can occur.
Dosing 1000 to 1500 mg/day P.O. twice a day.
Contraindications Pregnancy, severe gastrointestinal, or renal disease.
Main drug interactions Live virus vaccines. Macrolide antibiotics decrease mycophenolate blood levels, whereas acyclovir and related drugs may increase levels.
Main side effects Gastrointestinal symptoms can be severe and myelosuppression.
Special points Patients require periodic blood cell count monitoring and levels of liver and renal enzymes.
Cost/cost-effectiveness Very expensive
Interventional procedures

Plasma Exchange
Plasma exchange reduces serum levels of antibodies and is therefore useful for those PND of the peripheral nervous system directly mediated by antibodies. Plasma exchange also reduces circulating levels of cytokines and other mediators of inflammation that likely contribute to its effectiveness as an immunomodulatory therapy. Plasma exchange tends not to be useful for antibody-mediated PND of the central nervous system likely due to its inability to decrease intrathecal antibody titers.
Procedure Often performed every other day for a total of 5-6 exchanges. The exact number of exchanges should be adjusted for each patient. Some patients will require maintenance therapy on a monthly or less frequent basis.
Contraindications Poor medical condition, cardiac insufficiency, coagulopathy.
Complications Hypotension, cardiac arrhythmias, clotting abnormalities, electrolyte disturbances, muscle cramping, and infection at catheter site.
Special points Must be performed in hospital setting, usually requires indwelling catheter.
Cost/cost-effectiveness Expensive. For some disorders patients may have dramatic responses, and thus the cost of the procedure outweighs the cost of long-term medical care for the untreated patient.
Protein A Column Immunoadsorption
Although the exact mechanism of action of protein A immunoadsorption is not well understood, data suggest that it results in a reduction of circulating IgG antibodies and immune complexes and an increase in natural killer cell activity.
Procedure There is no set standard procedure. In one reported clinical trial patients were treated with protein A immunoadsorption therapy twice a week for 3 weeks for a total of 6 sessions [26] . At each session approximately 250-300 ml of plasma were perfused over the column.
Symptomatic and Supportive Therapy
Patients with brainstem or cerebellar dysfunction may require wheelchairs and feeding tube placement. Seizures associated with encephalitis often respond to conventional antiepileptics. Neuropathic pain and sensory dysesthesias in patients with neuropathies may be treated with antidepressants, including the tricyclics (e.g., amitriptyline) and the selective serotonin reuptake inhibitors, duloxetine, and venlafaxine. The antiepileptic drugs, gabapentin and pregabalin, also may be useful in some patients. For severe pain, tramadol and opioids are available.
Pediatric Considerations
The most commonly encountered paraneoplastic syndrome in children is opsoclonus-myoclonus occurring in children with neuroblastoma [27] . Treatment of the tumor and corticosteroids, adrenocorticotropic hormone, plasma exchange, IVIg, or rituximab, result in improvement in one half to two thirds of patients, although many children have residual cognitive and behavioral deficits [28] . Anti-NMDA receptor encephalitis is increasingly recognized in the pediatric population and, as in adults, often is responsive to immunotherapy. Tumors (usually teratoma) may occur in children, but the disorder is more often not paraneoplastic in this population [29] .
Other procedures: Antineuronal antibody testing
Any PND may occur without associated antibodies, and antineuronal antibodies are occasionally found at low titers in patients with cancer without neurologic symptoms [30] . If an antibody is found, but is one not usually associated with the patients' neurologic syndrome, other causes for the neurologic dysfunction should be considered. Similarly, if the detected cancer is not the histologic type typically found in association with the antibody a second neoplasm should be suspected. When PND affect the brain, spinal cord, or dorsal root ganglia, antibody titers will be higher in the CSF than serum. Therefore, if serum tests negative and there is suspicion of PND, CSF must be studied. This also may provide other supporting evidence of PND, such as the presence of inflammatory cells.
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